Estimating the prevalence of hepatitis delta virus infection among adults in the United States: A meta-analysis.
foreign‐born
hepatitis B
hepatitis D
meta‐analysis
prevalence
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
02 Apr 2024
02 Apr 2024
Historique:
revised:
05
03
2024
received:
06
02
2024
accepted:
19
03
2024
medline:
2
4
2024
pubmed:
2
4
2024
entrez:
2
4
2024
Statut:
aheadofprint
Résumé
Suboptimal awareness and low rates of hepatitis delta virus (HDV) testing contribute to underdiagnosis and gaps in accurate estimates of U.S. HDV prevalence. We aim to provide an updated assessment of HDV prevalence in the U.S. using a comprehensive literature review and meta-analysis approach. A comprehensive literature review of articles reporting HBsAg seroprevalence and anti-HDV prevalence was conducted to calculate country-specific rates and pooled prevalence of CHB and HDV using meta-analyses. Country-specific CHB and HDV rate estimates were combined with number of foreign-born (FB) persons in the U.S. in 2022 from U.S. Census Bureau to estimate total numbers of FB with CHB and HDV, respectively. These estimates were further combined with updated estimates of U.S.-born persons with CHB and HDV to yield the total number of persons with CHB and HDV. In 2022, we estimated 1.971 million (M) (95% CI 1.547-2.508) persons with CHB; 1.547 M (95% CI 1.264-1.831) were FB and 0.424 M (95% CI: 0.282-0.678) were U.S.-born. The weighted average HDV prevalence among FB persons in the U.S. was 4.20% (64 938 [95% CI 33055-97 392] persons), among whom 45% emigrated from Asia, 25% from Africa, and 14% from Europe. When combined with updated estimates of U.S.-born persons with HDV, we estimate 75 005 (95% CI: 42187-108 393) persons with HDV in the U.S. Including both FB and U.S.-born persons, we estimated that 1.971 M and 75 005 persons were living with CHB and HDV, respectively, in the U.S. in 2022.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Suboptimal awareness and low rates of hepatitis delta virus (HDV) testing contribute to underdiagnosis and gaps in accurate estimates of U.S. HDV prevalence. We aim to provide an updated assessment of HDV prevalence in the U.S. using a comprehensive literature review and meta-analysis approach.
METHODS
METHODS
A comprehensive literature review of articles reporting HBsAg seroprevalence and anti-HDV prevalence was conducted to calculate country-specific rates and pooled prevalence of CHB and HDV using meta-analyses. Country-specific CHB and HDV rate estimates were combined with number of foreign-born (FB) persons in the U.S. in 2022 from U.S. Census Bureau to estimate total numbers of FB with CHB and HDV, respectively. These estimates were further combined with updated estimates of U.S.-born persons with CHB and HDV to yield the total number of persons with CHB and HDV.
RESULTS
RESULTS
In 2022, we estimated 1.971 million (M) (95% CI 1.547-2.508) persons with CHB; 1.547 M (95% CI 1.264-1.831) were FB and 0.424 M (95% CI: 0.282-0.678) were U.S.-born. The weighted average HDV prevalence among FB persons in the U.S. was 4.20% (64 938 [95% CI 33055-97 392] persons), among whom 45% emigrated from Asia, 25% from Africa, and 14% from Europe. When combined with updated estimates of U.S.-born persons with HDV, we estimate 75 005 (95% CI: 42187-108 393) persons with HDV in the U.S.
CONCLUSIONS
CONCLUSIONS
Including both FB and U.S.-born persons, we estimated that 1.971 M and 75 005 persons were living with CHB and HDV, respectively, in the U.S. in 2022.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Gilead Sciences
Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Asselah T, Rizzetto M. Hepatitis D virus infection. N Engl J Med. 2023;389:58‐70.
Elsaid MI, Li Y, John T, Narayanan N, Catalano C, Rustgi VK. Economic and health care burdens of hepatitis delta: a study of commercially insured adults in the United States. Hepatology. 2020;72:399‐411.
Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. 2012;32:228‐236.
Kamal H, Westman G, Falconer K, et al. Long‐term study of hepatitis delta virus infection at secondary care centers: the impact of viremia on liver‐related outcomes. Hepatology. 2020;72:1177‐1190.
Kushner T, Serper M, Kaplan DE. Delta hepatitis within the veterans affairs medical system in the United States: prevalence, risk factors, and outcomes. J Hepatol. 2015;63:586‐592.
Niro GA, Smedile A, Ippolito AM, et al. Outcome of chronic delta hepatitis in Italy: a long‐term cohort study. J Hepatol. 2010;53:834‐840.
Romeo R, Del Ninno E, Rumi M, et al. A 28‐year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136:1629‐1638.
Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat. 2010;17:749‐756.
Wong RJ, Kaufman HW, Niles JK, et al. Low performance of hepatitis delta virus testing among 2 national cohorts of chronic hepatitis B patients in the United States. Am J Gastroenterol. 2022;117:2067‐2070.
Safaie P, Razeghi S, Rouster SD, Privitera I, Sherman KE. Hepatitis D diagnostics:utilization and testing in the United States. Virus Res. 2018;250:114‐117.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol. 2023;79:433‐460.
Wedemeyer H, Aleman S, Brunetto MR, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. 2023;389:22‐32.
Chen HY, Shen DT, Ji DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta‐analysis. Gut. 2019;68:512‐521.
Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta‐analysis. J Hepatol. 2020;73:523‐532.
Shen DT, Ji DZ, Chen HY, Goyal H, Pan S, Xu HG. Hepatitis D: not a rare disease anymore: global update for 2017‐2018. Gut. 2020;69:786‐788.
Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221:1677‐1687.
Wong RJ, Brosgart CL, Welch S, et al. An updated assessment of chronic hepatitis B prevalence among foreign‐born persons living in the United States. Hepatology. 2021;74:607‐626.
Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign‐born persons living in the United States by country of origin. Hepatology. 2012;56:422‐433.
U.S. Census Bureau. American Community Survey 1‐Year Estimates Public Use Microdata Sample 2021. 2022 [cited; Variables Place of birth (Recode) and Year of entry]. Accessed September 1, 2024. https://data.census.gov/mdat/#/search?ds=ACSPUMS1Y2021&cv=YOEP&rv=POBP&wt=PWGTP
Le MH, Yeo YH, Cheung R, Henry L, Lok AS, Nguyen MH. Chronic hepatitis B prevalence among foreign‐born and U.S.‐born adults in the United States, 1999‐2016. Hepatology. 2020;71:431‐443.
Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of chronic hepatitis B virus infection in the United States. Am J Gastroenterol. 2020;115:1429‐1438.
U.S. Census Bureau. American Community Survey 1‐Year Estimates. 2022 [cited; Place of Birth by Nativity and Citizenship Status]. Accessed September 1, 2024. https://data.census.gov/table?q=B05002:+PLACE+OF+BIRTH+BY+NATIVITY+AND+CITIZENSHIP+STATUS&tid=ACSDT1Y2021.B05002
Polaris Observatory Collaborators. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories. J Hepatol. 2024;80(2):232‐242.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546‐1555.
Khalfi P, Kennedy PT, Majzoub K, Asselah T. Hepatitis D virus: improving virological knowledge to develop new treatments. Antivir Res. 2023;209:105461.